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Before the discovery of peroxisome proliferator activated receptors (PPARs), it was well known that certain drugs considered as
classical PPAR-alpha agonists induced hepatocarcinoma or peroxisome proliferation in rodents. These drugs were derivatives of
ﬁbric acid, and they included cloﬁbrate, bezaﬁbrate, and fenoﬁbrate. However, such toxicity has never been observed in human
patients treated with these hypolipidemic drugs. Thiazolidinediones are a new class of PPAR activators showing greater speciﬁcity
for the γ isoform of PPARs. These drugs are used as insulin sensitizers in the treatment of type II diabetes. In addition, they have
been shown to induce cell diﬀerentiation or apoptosis in various experimental models of cancer. PPAR-α ligands have also been
shown to induce cancer cell diﬀerentiation and, paradoxically, PPAR-γ drug activators have been reported to act as carcinogens.
Theconfusingpicturethatemergesfromthesedataisfurthercomplicatedbytheseriesofintriguingsideeﬀectsobservedfollowing
administration of pharmacological PPAR ligands (rhabdomyolysis, liver and heart toxicity, anemia, leucopenia). These side eﬀects
cannotbeeasilyexplainedbysimpleinteractionsbetweenthedrugandnuclearreceptors.Rather,thesesideeﬀectsseemtoindicate
that the ligands have biological activity independent of the nuclear receptors. Considering the emerging role of mitochondria in
cancer and the potential metabolic connections between this organelle and PPAR physiology, characterization of the reciprocal
inﬂuences is fundamental not only for a better understanding of cancer biology, but also for more deﬁned pharmacotoxicological
proﬁles of drugs that modulate PPARs.
Copyright © 2008 Roberto Scatena et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Since the discovery of the ﬁrst PPAR by Issemann and Green
in 1990 [1], the role of this fascinating class of nuclear recep-
tors in normal physiology and pathophysiology has become
progressivelymoreimportant.Thepotentialbiologicalactiv-
itiesattributedtoPPARshavebeenexpandingeversincethey
were identiﬁed as potential mediators of the hypolipidemic
eﬀectofﬁbratesinhumansandasparticipantsinperoxisome
proliferation and hepatocarcinogenicity in rodents. So far,
PPARs have been implicated in diverse processes including
lipid and carbohydrate metabolism, energy expenditure,
immune and inﬂammatory processes, vascular homeostasis,
tissue remodeling, and cell diﬀerentiation and proliferation
in normal and neoplastic tissues [2–8].
It is evident, but too often ignored, that important
interrelationships must exist among PPARs, mitochondria,
andcancer.Regardlessoftheprecisenatureoftheseintercon-
nections, PPARs undoubtedly have a signiﬁcant energetic,
plastic, and signaling role in the pathophysiology of cancer
cellspurelybyvirtueoftheircentralroleinlipidmetabolism.
This role necessarily involves interaction with mitochondria.
Mitochondria are not only the main site of lipid oxidative
metabolism, but they are also the cellular powerhouses that
coordinate cellular metabolism and serve as the origin of
important anabolic ﬂuxes and signal transduction pathways
[9, 10].
Thus, the role of mitochondria in cancer is under a
critical re-evaluation, particularly in light of the so-called
Warburg eﬀect: most cancer cells exhibit increased aerobic
glycolysis, and use this metabolic pathway for generation of
ATP as a main source of their energy supply. Too often this
does not justify the complex metabolic alterations present in
diﬀerent types of neoplasia [11–13].
Similarly, the interrelationships between PPARs and
cancer are not entirely clear. Some studies show that PPARs2 PPAR Research
have antineoplastic and/or cancer diﬀerentiating activities,
while others show that they have important carcinogenic
properties [6, 14–20].
These reports highlight the multifaceted role of PPARs
in neoplastic cells. Hence, the roles of PPAR in normal
physiology and pathophysiology should be clariﬁed, since
thismaybeneﬁtourunderstandingofhowcanceroccursand
how it can be treated.
Discussionoftheinterrelationships amongPPARs,mito-
chondria, and cancer should ﬁrst involve careful evaluation
of some misleading factors that have contributed to confu-
sion about PPAR biology.
2. PPARs IN PATHOPHYSIOLOGY AND
MISLEADING FACTORS
2.1. Syntheticligands
Initially, the physiological ligands of PPARs were unknown
and PPARs were classiﬁed as “orphan receptors.” Their
function was studied using synthetic ligands of PPAR-α, the
ﬁrst PPAR discovered. These synthetic ligands were a het-
erogeneous class of molecules ranging from trichloroacetic
acid to plasticizers such as di-2-ethylhexyl phthalate (DEHP)
and mono-2-ethylhexyl phthalate (MEHP) [1]. The struc-
tural heterogeneity of the ligands seems to reﬂect the
conformation of the PPAR ligand binding domain (LBD),
which forms a large, Y-shaped hydrophobic pocket with
relatively low ligand speciﬁcity [2, 7]. For PPAR-α, the
ligands used most often in experiments were ﬁbrates such
as cloﬁbric acid, bezaﬁbrate, and gemﬁbrozil. Studies on
ﬁbrate binding to PPAR-α showed that these drugs caused
a hypotriglyceridemic eﬀect by inducing transcription of
several genes related to oxidative metabolism of lipids,
which occurs primarily in the mitochondria [2–4]. However,
some discrepancies soon emerged. In fact, previous PPAR
research failed to provide thorough explanations of the
drugs’ other important biological activities, such as per-
oxisome proliferation and hepatocarcinogenicity in rodents
or, most importantly, their side eﬀects. These side eﬀects
include angina crisis; elevation of serum aminotransferase,
which indicates liver damage; increases in serum creatine
phosphokinase concentrations, which can initiate myositis,
myopathy and, in rare cases, rhabdomyolysis; increases in
serum creatinine concentration; and acute renal failure in
rare cases [21].
Some of these biological activities had already led
investigators to propose that these ligands had eﬀects inde-
pendent of their binding to PPAR. If true, neglecting these
“extrareceptor” functions may interfere with our under-
standing of PPAR pathophysiology. For example, studies in
the 1980s established that ﬁbrates (cloﬁbric acid, bezaﬁbrate,
and gemﬁbrozil) can pass freely through red blood cell
membranes and bind to human hemoglobin at the level
of the hydrophobic pocket of the alpha chain interfaces.
This binding lowers the oxygen aﬃnity of hemoprotein
more strongly than does the natural allosteric eﬀector 2,3-
biphosphoglycerate [22], which could, for example, lead
to an angina crisis (by perturbation of microcirculation in
ischemic areas caused by abrupt changes in the level of
oxygen released from the blood) at the usual therapeu-
tic plasmatic drug concentrations [23]. Around the same
time, other researchers showed that the agents acting as
peroxisome proliferators hampered mitochondrial respira-
tion, with potentially signiﬁcant clinical implications [24–
26]. Indeed, treatment with ﬁbrates was found to lead to
some histological and biochemical features characteristic of
hepatic, muscular, and renal toxicities. This result led to the
hypothesis that disruption of the mitochondrial electron res-
piratory chain in conjunction with other genetic or acquired
predisposing factors may contribute to these toxic eﬀects
independently of PPAR activation. Moreover, molecular
analysis of the interactions between human hemoglobin and
ﬁbrates indicated that particular physicochemical aspects of
the drug molecules, speciﬁcally their carboxylic group and
their signiﬁcant hydrophobicity, might be responsible for
their biological activity. Interestingly, these physicochemical
characteristics of ﬁbrates ﬁt well with the milieu of mito-
chondria in general, namely the diﬀerence in pH between
themorealkalinematrixandthemoreacidicintermembrane
space,aswellaswithstructuralfeaturesofcomplexI(NADH
cytochrome c reductase) in the mitochondrial electron
respiratory chain, which is a large, hydrophobic protein
component in the mitochondria [10, 27].
All of these considerations led to studies that examined
how mitochondria were aﬀected by ﬁbrate administration,
and whether these eﬀects might have clinical implications
[18, 28]. The results clearly showed that ﬁbrates could
disrupt the mitochondrial electron respiratory chain at the
level of NADH cytochrome c reductase [18]. This eﬀect was
even more pronounced for ciglitazone, which was one of the
ﬁrstthiazolidinedionestobesynthesized.Thiazolidinediones
are a class of molecules that are chemically related to ﬁbrates
(Figure 1). Drug-induced mitochondrial dysfunction causes
a series of compensatory metabolic mechanisms, which, in
addition to PPAR agonist activity, may be partially respon-
sible for some of the pharmacological and toxicological
properties of this class of molecules. In fact, the resulting
shut-down of mitochondrial NADH oxidation drives cells
to change their oxidative metabolism in a way that is
strictly correlated to the degree of complex I inhibition.
Speciﬁcally, upon treatment with ﬁbrates, which are less
potent inhibitors of complex I, cells tend to use those
components of the electron respiratory chain that remain
eﬃcient (e.g., complex II). This leads the cell to use FADH2
oxidation to obtain energy. In other words, compensatory
mechanisms come into play, which are probably sustained
by glycerol catabolism viamitochondrial FAD-dependent
glycerol-3-phosphate dehydrogenase or by fatty acid β-
oxidation viaelectron-transferring ﬂavoprotein (ETF). These
changes have a signiﬁcant hypotriglyceridemic eﬀect and a
slight hypoglycemic eﬀect. In contrast, using more potent
complex I inhibitors (i.e., thiazodilinediones) greatly reduces
NADH dehydrogenase activity, thus reducing the use of β-
oxidation and increasing reliance on glycolysis, resulting in
as t r o n g e rh y p o g l y c e m i ce ﬀect and a much weaker or null
hypotriglyceridemic eﬀect (Figure 2)[ 18].
Based on these ﬁndings, PPAR-α activation may be due,
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Figure 2: Flow chart of possible molecular mechanisms caused by a mitochondrial dysfunction induced by ﬁbrates (PPAR-α ligands) and
thiazolidinediones (PPAR-γ ligands).
use of lipids through glycerol catabolism via mitochondrial
FAD-dependent glycerol-3-phosphate dehydrogenase and
fatty acid β-oxidation via ETF. In this way, as suggested
by Kersten et al. [3], fatty acids would stimulate their own
metabolism. Interestingly, this mechanism of switching to
lipid metabolism in response to ﬁbrate-induced complex I
inhibition may explain the reported activation of genes in
the cytochrome P450 IV family. This family of proteins is
responsible for microsomal ω-oxidation of long chain and
very long chain fatty acids [29]. This pathogenic mechanism
may also provide a better explanation of the peroxisomal
proliferation observed in rodents given synthetic PPAR-α
ligands. In fact, the lipid component of these animals’ diet
contains a particularly high proportion of polyunsaturated
fatty acids [30]. Hence peroxisomal β-oxidation, which
is normally more active in rodents than in humans or
other primates, may be further enhanced by inhibition of
mitochondrial NADH oxidation.
Moreover, the increase in free radical oxygen species
resulting from stimulated peroxisomal β-oxidation may
furtherincreasetheoxidativestressthatresultsfromcomplex
I inhibition [31, 32] and thereby contributes signiﬁcantly
to the observed carcinogenic properties of PPAR ligands in
rodents, particularly in the liver.
From a clinical point of view, thiazolidinediones, which
are stronger inhibitors of NADH cytochrome c reductase4 PPAR Research
[18, 33–36] than ﬁbrates, strongly disrupt NADH oxidation
such that they may prevent the induction of β-oxidation,
which could otherwise serve as a compensatory energy
source. This renders metabolism almost exclusively depen-
dent on glycolysis. Interestingly, damage to the pathways of
energy production, particularly in organs that are rich in
mitochondria (e.g., liver, muscle, heart, and kidney), may
explain (i) the prevalent hypoglycemic activity of γ-ligands,
despiteminor orabsenthypolipidemic eﬀects,(ii)theweight
gain due mainly to water retention typically observed in
patients treated with PPAR-γ ligands, (iii) the diﬀerentiation
of adipose cells, and (iv) the dramatic cardiac and hepatic
toxicities often observed following administration of thiazo-
lidinediones [37–40].
Interestingly, similar mitochondrial impairment by
PPAR agonists was observed by Nadanaciva et al. [41],
who used a phosphorescent oxygen-sensitive probe and an
immunocapture technique to evaluate the mitochondrial
respiration and the activity of individual oxidative phospho-
rylationcomplexesonisolatedratlivermitochondria.Bythis
dual approach, the authors were also able to obtain a rank
order of the mitochondrial toxicity of thiazolidinediones,
ﬁbrates, and statins. These results could be important as
they suggest the possibility of a screening strategy to evaluate
potential mitochondrial toxicity, reducing in such a way the
incidence of clinical side eﬀects.
Moreover, a novel mitochondrial target protein has
recently been identiﬁed for the thiazolidinediones [42].
This protein, called mitoNEET, is an iron-containing outer
mitochondrial membrane protein that seems to play a role
in regulating mitochondrial oxidative processes. Recently,
Wiley et al. [43, 44] showed that cardiac mitochondria
isolated from mitoNEET-null mice demonstrated a reduced




ing the direct interrelationships between pharmacological
PPAR ligands and mitochondria, also to better clarify the
physiology and pathophysiology of PPARs.
In conclusion, many PPAR ligands possess extrareceptor
biological activities that can complicate interpretation of the
results of experiments investigating the pathophysiology of
PPARs. This caveat has serious consequences, not only for
our ability to correctly understand the metabolic roles of
PPARs, but also for our ability to determine their roles in the
(de)diﬀerentiation of cancer cells.
2.2. MetabolicandgeneticstudiesofPPARsinrodents
Most of the available data on the pathophysiology of
PPARs has been obtained from metabolic studies in rodents.
However, species-speciﬁc diﬀerences in metabolism and diet
can be an obstacle when applying the results of animal
studies to human patients [35, 45].
Another source of data that may be misleading is genetic
studies on knock-out rodents for PPARs or their transcrip-
tional coactivators (i.e., PGC-1α). Conclusions drawn from
thesestudiesaboutthemetabolicrolesofthediﬀerentPPARs
neglect the interaction between PPARs and their coactivators
inmitochondrialbiogenesisingeneral,andinmitochondrial
lipid metabolism in particular [5, 46–49].
3. PPAR AND CANCER: WHAT IS THE ROLE
FOR MITOCHONDRIA?
Various molecular links between PPARs and cancer have
been considered in other articles. Here, we highlight some
intriguing observations related to PPARs and cancer that
seem to indicate a role for mitochondria in this disease of cell
proliferation and diﬀerentiation. Since the aim of this review
is to discuss the potential molecular link between PPARs and
cancer from a mitochondrial point of view, we focus on the
particular “extrareceptor” interrelationships between PPARs
and ﬁbrates or their thiazolidinedione derivatives.
3.1. PPARs,mitochondria,andcarcinogenesis
PPARs and their pharmacological ligands were originally
consideredtobe“oncopromoters.”Speciﬁcally,PPARligands
were considered to be nongenotoxic carcinogens. It is well
known that these molecules can induce hepatocarcinoma
in rodents; however, their administration ﬁrst provokes
hepatomegalia and induces expression of a series of antiox-
idant enzymes, such as catalase, superoxide dismutase, and
glutathione peroxidase. In this way, these molecules may
create an imbalance in oxidative metabolism in general and
oxidative stress in particular [50, 51]. The ability of PPAR
ligands to induce oxidative stress has since been conﬁrmed
for thiazolidinediones as well [52–54]. Interestingly, reactive
oxygen species (ROS) and cellular oxidative stress have
long been implicated in carcinogenesis, despite the fact that
the precise pathogenic molecular mechanisms are complex,
debated, and at times paradoxical [55]. More speciﬁcally, the
following hold.
(i) In normal cells, mutations in nuclear or mitochon-
drial genes encoding components of the mitochon-
drial electron transport chain (ETC) or xenobiotics
capable of disrupting the mitochondrial electron
ﬂux can lead to an increase in the generation of
ROS, particularly superoxide. This radical is rapidly
dismuted by superoxide dismutase to yield hydrogen
peroxide (H2O2), which can diﬀuse to the nucleus
and attack DNA before cellular antioxidant defenses
adjust to the new level of oxidative stress. This oxida-
tive damage may contribute to genetic instability
in congenital and/or acquired predisposed subjects
[56, 57].
(ii) Cancer cells generally generate more ROS than
normal cells. This diﬀerence may relate to the greater
number of metabolic and proliferative activities that
oftenoccurinatransformedcell,ortoaqualitativeor
quantitative imbalance between cellular antioxidant
defenses and the oxidative environment [55, 58–60].
(iii) In cancer cells, the levels of expression of some
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independently by drug treatment (e.g., thioredoxin,
DJ-1 protein, peptidyl-prolyl cis-trans isomerase A,
cyclophilin A, protein disulﬁde isomerase A3, ERP
60/GRP58) [55, 61]. Interestingly, the increase in
thioredoxin activity in cells with elevated oxidative
stress may relate to its essential role in facilitating
transcription in an environment where increased
oxidative stress signaling in the cytosol is required
for stimulating cell proliferation. Furthermore, drug-
induced cancer cell diﬀerentiation typically reduces
the expression of these antioxidant proteins [62].
(iv) Numerous studies implicate increased oxidative
stress in the cell death induced by diverse chemother-
apeutic agents. Anthracycline derivatives, newer
redox cycling agents, and, more recently, histone
deacetylase inhibitors and proteasome inhibitors all
appear to increase oxidative stress in cells. Although
the mechanism responsible for the increase has not
been established, mitochondria are fundamental in
ROS generation and seem to be involved, either
directly or indirectly [55, 63–65].
This puzzling picture suggests that PPAR-related rodent
hepatocarcinogenesis depends on strong stimulation of ROS
generation, mainly in mitochondria dysregulated by the
PPAR ligand in question. Moreover, this oxidative stress
may be reinforced by the speciﬁc membrane composition
and the abundant H2O2 production from peroxisomal lipid
metabolism in rodents, as already discussed.
Could a similar pathogenic mechanism have a role in
human carcinogenesis?
A direct role for PPARs in carcinogenesis is hardly
credible, considering their fundamental physiological role in
cell metabolism. The altered expression of diﬀerent PPAR
isoforms observed in some neoplasias may be the result of
secondary metabolic changes in transformed cells relative to
normal cells [6, 66].
On the other hand, the question of whether the synthetic
PPARligandsplayaroleinhumancarcinogenesisisstillopen
and intriguing. In fact, one of the ﬁrst large clinical studies
on gemﬁbrozil, a classic PPAR-α ligand, [67] showed a small
but signiﬁcant increase (P = .032 by the Fisher exact test) in
theincidenceofbasalcellcarcinomainpatientstakinggemﬁ-
brozil;thisﬁnding,unfortunatelyhasbeenlargelyignoredby
investigators. Moreover, in an intermediate follow-up study
[68], cancer occurred at equal rates in both the untreated
group and the group treated with gemﬁbrozil, but the cancer
in the latter led more often to mortality, primarily during
the last 1.5 years of follow-up. To be sure, results recently
obtained from an 18-year mortality follow-up of this study
do not seem to conﬁrm this increase in cancer mortality,
but the follow-up design failed to address certain possible
interpretations and also in the Autors opinion of this cited
study some of the follow-up data can be misleading [69].
Nevertheless, the data obtained in the original study are
intriguing considering the peculiar molecular epidemiology
and pathogenesis of basal cell carcinoma and the relatively
short (5-year) period of drug exposure used in the study.
These ﬁndings, together with the demonstrated ability
of ﬁbrates and thiazolidinediones to alter mitochondrial
oxidative metabolism and induce ROS generation, indicate
that care should be taken when this class of drugs is used in
the treatment of nutrition-sensitive tumors [70, 71].
3.2. PPARs,mitochondria,andinhibitionof
tumorgrowth
It is well established that activation of PPARs (α, β/δ,
and γ) by natural or synthetic agonists can inhibit growth
and induce diﬀerentiation or death of tumor cells. The
originalobservationwasofPPAR-γ ligandsandliposarcoma,
consistent with the physiological function of PPAR-γ [3, 72,
73]. Subsequently, PPAR-γ and PPAR-α ligands were shown
to promote the diﬀerentiation of various tumor cell lines,
including breast, lung, prostate, leukemia, colon, melanoma,
and liver. This diﬀerentiation was often independent of the
relative expression levels of the diﬀerent PPAR isoforms [6,
15, 16, 66, 70, 72]. These studies also suggested extrareceptor
activities of ﬁbrates and thiazolidinediones as the basis of
their ability to induce cancer cell diﬀerentiation [15–18,
72]. Moreover, a recent study by Panigrahy et al. [74, 75]
on endothelial and mesenchymal tumor cells and mice
showed that PPAR-α ligands such as fenoﬁbrate directly
suppress tumor growth through receptor-dependent and -
independent pathways, and that they indirectly suppress
tumor growth by inhibiting angiogenesis and the inﬂam-
matory response in the microenvironment of the tumor.
Therefore, the noncancerous host tissue could be an impor-
tant target for cancer treatment with pharmacological PPAR
ligands.
These data illustrate the extreme complexity of the
interrelationships among PPARs, mitochondria, and cancer.
Nevertheless, the most important aspects of these interre-
lationships are the activities of the synthetic PPAR ligands,
particularly their extrareceptor activities. Mitochondria are
becoming increasingly important as targets for these drug-
induced extrareceptor activities, as discussed in recent
reviews [35, 76, 77]. To better understand the interactions
among PPAR ligands, mitochondria, and cancer, it may be
useful to describe our work, which parallels that of other
groups. Curiously, the diﬀerentiating activity of ﬁbrates was
originally hypothesized in binding studies of ﬁbrates and
hemoglobin. The physicochemical properties of ﬁbrates and
their toxicological proﬁle allow them to interact with some
hydrophobic components of the mitochondrial electron res-
piratory chain. The resulting oxidative metabolic stress may
induce diﬀerentiation of cancer cells, similar to the eﬀects
of heat shock [15]. Importantly, this eﬀect does not depend
on PPAR agonism, but it is related to the physicochemical
properties(pKa,logP,logD,watersolubility,andpHproﬁle)
of the molecules. These properties should favor permeation,
accumulation, and interaction with components of the
internal mitochondrial membrane [10].
For example, therapeutic doses of bezaﬁbrate inhibited
proliferation of human leukemia cell lines HL-60, U-937,
and K-562 in a dose-dependent manner. In HL-60 cells,
growth inhibition was associated with an increased number
of cells in the G0/G1 phase and a signiﬁcant decrease6 PPAR Research
in the number of cells in the G2/M phase. Analysis of
cell diﬀerentiation markers (CD) showed a dose-dependent
increase in expression of CD11b and CD14 in HL-60 cells
and of CD14 in U-937 cells. Functional assays conﬁrmed
that the phenotypes of these cells were more mature.
Both HL-60 and U-937 cells showed a dose-dependent
restoration of the respiratory burst stimulated by PMA
and zymosan. K-562 erythroleukemia cells showed a dose-
dependent increase in hemoglobin synthesis. Similar cellular
diﬀerentiation was observed following treatment with two
other ﬁbrate derivatives, cloﬁbric acid and gemﬁbrozil.
Interestingly, ﬁbrate-induced diﬀerentiation was partially
inhibited by antioxidants including acetylcysteine (NAC),
and electron microscopy revealed that ﬁbrate-treated cells
had mitochondrial damage [15]. Functional evaluation of
this drug-induced mitochondriopathy showed that ﬁbrates
and ciglitazone speciﬁcally inhibited NADH cytochrome c
reductase activity in a dose-dependent manner in HL-60,
TE-671humanrabdomyosarcoma,andHep-G2humanhep-
atocarcinoma cell lines, whereas the activity of other mito-
chondrial respiratory chain enzymes remained unchanged
[18, 33, 36]. The impairment of NADH oxidation induced a
cellular metabolic shift towards anaerobic glycolysis and/or
β-oxidation, as shown by the dose-dependent increases of
certain metabolites (lactate, alanine, glycolytic, and nongly-
colytic derived acetate) [18].
A fundamental observation from this research was the
correlation of mitochondrial dysfunction, metabolic shift,
and diﬀerentiation activity in tumor cells treated with
increasing concentrations of PPAR ligands. Furthermore,
quantitativecomparisononamolarratiobasisbetweenthese
PPAR ligands (bezaﬁbrate, cloﬁbric acid, gemﬁbrozil, and
ciglitazone) for inhibition of NADH cytochrome c reductase
activity, metabolic adaptations, diﬀerentiation potency, and
antiproliferativeindexconﬁrmedastrictcorrelationbetween
theseparameters[18].Theseresultssuggestedthatinhibition
of mitochondrial NADH dehydrogenase could contribute to
boththepharmacologicalandtoxicologicalproﬁlesofﬁbrate
derivatives (strong hypolipidemic/weak hypoglycemic eﬀect,
liver and muscle toxicity) and thiazolidinediones (hypo-
glycemic/insulin sensitizer eﬀect, liver and heart toxicity)
[17, 18, 25, 26, 33–40].
In terms of mitochondrial oncology, these data sug-
gest a possible molecular mechanism for the peroxisome
proliferator activity and carcinogenicity of ﬁbrates typically
observed in rodents. These data also indicate a strict correla-
tion among ﬁbrate- and thiazolidinedione-induced cellular
respiration dysfunction, stimulation of glycolysis, and cancer
celldiﬀerentiationthatstronglyimplicatesmitochondriaand
oxidative metabolism in the pathophysiology of cancer.
Importantly, these results conﬁrm and extend the results
of other studies focusing on nongenomic activities of ﬁbrates
and thiazolidinediones [16, 17, 78–81]. Furthermore, these
observations explain some contradictory data related to the
role of PPARs in cancer cell diﬀerentiation [3, 6, 72, 77].
Above all, the intriguing data concerning the induction
of diﬀerentiation associated with a shift towards aerobic
glycolysis (a paradoxical Warburg eﬀect) conﬁrms the need
to reconsider cancer cell metabolism in general and the
Warburg eﬀect in particular [11, 13, 82]. To that end, our
understanding of the role of PPARs in cancer should assume
a new level of complexity that takes into account their
fundamental functions in lipid metabolism, in inﬂammation
and, directly or indirectly, in angiogenesis [74, 75].
The molecular link among the synthetic PPAR ligands,
mitochondria, and cancer indicates the need for a careful
evaluation of some aspects of cancer cell pathophysiology,
such as the following.
(i) The possible existence of a transduction pathway
master signal as the basis of the complex cellular
diﬀerentiation program related to PPAR. ROS, nitric




(ii) The role of some oncogenes/oncosuppressors in
cancer pathogenesis, given that mitochondrial respi-
ratory chain dysfunction can induce a more diﬀeren-
tiatedphenotypeintumorcellsandtherebyinﬂuence
their activity [15–18].
(iii) The signiﬁcance of the modulation of the expression
of proteins with oncogenic and antioxidant functions
(stathmin 1, DJ-1 protein, peroxiredoxin 2, nucle-
oside diphosphate kinase A, etc.) in PPAR-related
cancer cell diﬀerentiation. This is an important topic
given the potential pathophysiological role of PPAR
in cancer [62, 83].
At last, an understanding of the molecular mechanisms
involved in the interrelationships between mitochondrial
respiration and PPAR-related cancer regression may have
important clinical implications for cancer diagnosis, prog-
nosis, and therapy.
4. CONCLUSION
Many molecular mechanisms have been proposed to explain
how PPARs, directly and/or indirectly, may induce cancer
cell cycle arrest and induction or cancer cell diﬀerentiation
or dediﬀerentiation. In spite of this, the molecular interrela-
tionships between the mechanisms of functional modulation
of PPAR and these important cellular phenotypic changes
are still debated. It is clear that the various molecular
modiﬁcations observed in diﬀerent studies (decrease in
cyclin D1, inhibition of IkB, induction of TSC22, NF-kB,
GADD153, PTEN, etc.) may depend on the particular cell
and cell functional status and that a potential master signal
should be investigated.
Here, we have brieﬂy described the molecular link
between PPARs and cancer from a mitochondrial point of
view. In our opinion, the most important factor linking
cancer to PPARs is represented by their “synthetic ligands,”
which are characterized by other important and debated
extrareceptor activities. Speciﬁcally, these agents can induce
oxidative stress, which has an ambiguous role in cancer,
leading it to act as a double-edged sword.Roberto Scatena et al. 7
In this sense, mitochondria plays a critical role as one
of the most important organelles for generating reactive
species. The metabolic stress and energetic failure that result
from ﬁbrate- and thiazolidinedione-induced mitochondrial
impairment may also play an important part in cancer
regression,especiallyincellsthatrequireactiveandcomplete
anabolic pathways to sustain cancer growth, an aspect that
has not always been completely or correctly evaluated.
Considering their physicochemical properties discussed
above, it is worthy of note that tumor regression induced by
PPAR ligands may be a useful approach for the treatment
of neoplasias of the central nervous system, which are
classically diﬃcult to treat with conventional chemotherapy.
Speciﬁcally, interesting results have already been obtained in
terms of decrease of cell proliferation, apoptosis induction,
and expression of markers typical of a more diﬀerentiated
phenotype in glioblastoma and astrocytoma cell lines [84–
90], in primary cultures of human glioblastoma cells derived
from surgical specimens [91], and above all, in patients with
high-gradegliomas(glioblastomaoranaplasticglioma)[92].
Moreover, given that pharmacological modulation of
PPAR in cancer cells typically arrests the cell cycle in
the G0/G1 phase, combination therapy with a PPAR ago-
nist and an antimitotic antitumor agent deserves careful
consideration.
Furthermore,itmaybeusefultodistinguishbetweenreal
diﬀerentiating agents, which show low cytotoxicity indices
relative to their diﬀerentiation activity (thiazolidinediones,
ﬁbrates,retinoids)andspuriousdiﬀerentiatingagents,which
show low diﬀerentiating activity and high cytotoxicity
indices (old and new HDAC inhibitors) [93, 94].
A mitochondrial approach to analysis of the molecular
link between PPARs and cancer certainly adds new levels
of complexity to the already complicated picture. However,
an optimal deﬁnition of all molecular mechanisms relating
PPARs, mitochondria, and cancer may be fundamental
to our understanding of the real therapeutic index of
pharmacological modulation of these nuclear receptors. This
is important not only in cancer, but also in the other diseases
in which PPARs play a signiﬁcant role, including atheroscle-
rosis, hyperlipoproteinemias, metabolic syndrome, diabetes
mellitus,andobesity.Moreover,acompleteunderstandingof
the pharmacotoxicologicalproﬁleof theseagentsmayreduce
the incidence of dangerous side eﬀects that have already
dramatically aﬄicted patients treated with PPAR ligands
[37–40].
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